ArticleFrontiers in oncology2026
Treatment with Mirvetuximab-Soravtansin-first clinical experience in advanced ovarian cancer in a comprehensive cancer center.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Mirvetuximab-Soravtansin (MIRV) is an antibody-drug conjugate (ADC) for the therapy of advanced platinum-resistant folate receptor α (FRα)-expressing ovarian cancer. The goal of the study was to treat patients with MIRV off-label in our Comprehensive Cancer Center regarding the outcome and adverse events. Methods: This retrospective single-center cohort study included six patients with advanced high-grade serous ovarian cancer (HGSOC) or high-grade serous primary peritoneal carcinoma (PPC) with initial FIGO stage IIC-IV between July 2023 and August 2024. Inclusion criteria were metastatic advanced HGSOC or PPC, expression of FRα ≥75% (IHC PS2+), and progression during systemic therapy with ≥3 therapies before. All patients underwent ophthalmological examination before therapy with MIRV. Results: After 2-6 cycles of MIRV (median, 3.3), objective descriptive response with computed tomography (CT) scan of the thorax-abdomen and CA-125 response were monitored. CA-125 decreased in all evaluable patients ( Discussion: Treatment with MIRV has been shown to be promising in advanced ovarian cancer. In a small heterogeneous group of heavily pretreated patients, general recommendations for therapy with MIRV are limited. Close collaboration with ophthalmology and patient education is essential to mitigate ocular events.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.